Hanmi Pharm. Co., Ltd.
Financials
Valuation Metrics
Hanmi Pharm. Co., Ltd.'s Market Cap is ₩6.5T. At end of 2025 it was ₩5.8T. Ranked #90 of 2,421 in KR market (top 4%), #85 of 781 on KOSPI (top 11%), #5 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 2%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 6.47T KRW | KR#90/2,421 Sec#5/231 |
| Revenue | 1.66T KRW | KR#294/2,421 Sec#9/231 |
| Net Income | 234.64B KRW | KR#127/2,421 Sec#4/231 |
| Total Assets | 2.33T KRW | KR#279/2,421 Sec#10/231 |
| Net Assets | 1.59T KRW | KR#212/2,421 Sec#8/231 |
| Employees | 2,388 | KR#123/2,421 Sec#3/231 |
| Value | ||
| P/E | 27.57x | KR#1,285/2,421 Sec#78/231 |
| P/B | 4.07x | KR#2,197/2,421 Sec#182/231 |
| PEG | 0.26x | KR#608/2,421 Sec#34/231 |
| P/S | 3.91x | KR#2,077/2,421 Sec#134/231 |
| EV/EBITDA | 20.64x | KR#1,028/2,421 Sec#62/231 |
| FCF Yield | 2.01% | KR#1,052/2,421 Sec#70/231 |
| Profitability | ||
| ROE | 14.77% | KR#334/2,421 Sec#23/231 |
| ROA | 10.05% | KR#273/2,421 Sec#21/231 |
| Op. Margin | 19.52% | KR#171/2,421 Sec#17/231 |
| Revenue Growth | 12.93% | KR#765/2,421 Sec#73/231 |
| Earnings Growth | 106.35% | KR#377/2,421 Sec#25/231 |
| Financial Health | ||
| Debt Ratio | 46.86% | KR#919/2,421 Sec#104/231 |
| Total Debt | 408.09B KRW | KR#348/2,421 Sec#14/231 |
| FCF | 130.05B KRW | KR#151/2,421 Sec#8/231 |
| Cash | 209.04B KRW | KR#259/2,421 Sec#9/231 |
| Current Ratio | 1.82x | KR#964/2,421 Sec#106/231 |
| Net Debt/EBITDA | 0.62x | KR#693/2,421 Sec#42/231 |
| Dividend | ||
| Div. Yield | 0.40% | KR#1,290/2,421 Sec#78/231 |
| Div. Growth | 60.00% | KR#201/2,421 Sec#7/231 |
| Performance | ||
| 1Y Return | 51.88% | KR#252/2,421 Sec#11/231 |
| 1M Return | 29.99% | KR#132/2,421 Sec#10/231 |
| From 52W High | -21.95% | KR#296/2,421 Sec#14/231 |
| 1Y MDD | -50.24% | KR#1,006/2,421 Sec#84/231 |
| Trading | ||
| Volume | 85,412 shares | KR#857/2,421 Sec#81/231 |
| Trading Value | 43.35B KRW | KR#89/2,421 Sec#3/231 |
| Foreign Own. | 13.74% | KR#351/2,421 Sec#23/231 |
| Per Share | ||
| EPS | 18,315 KRW | KR#56/2,421 Sec#3/231 |
| BPS | 124,041 KRW | KR#119/2,421 Sec#5/231 |
Company Info
Hanmi Pharmaceutical was established in 2010 through a spin-off of its pharmaceutical manufacturing and sales division, comprising three domestic and international subsidiaries. It produces Rosuzet, Amozaltan, and Esomezol, while Hanmi Fine Chemical exports cephalosporin-based antibiotics globally, and Beijing Hanmi Pharmaceutical Co., Ltd. sells various products. The company focuses on innovative new drug development, having acquired numerous patents by 2025, and is optimizing manufacturing processes and saving energy to reduce greenhouse gas emissions by 30% by 2030. Hanmi Pharmaceutical is headquartered in Hwaseong-si, Gyeonggi-do.